ArticleCVIR endovascular2026
Rotational atherectomy via retrograde popliteal access without embolic protection for complex femoropopliteal lesions.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur study aims to evaluate the technical feasibility and safety of retrograde popliteal artery access (RPA) combined with rotational atherectomy and drug-coated balloon (DCB) angioplasty for complex femoropopliteal lesions, specifically without the use of distal embolic protection devices (EPD).
methodsThis single-center, single-operator, retrospective study enrolled 22 consecutive patients with TASC B and C femoropopliteal lesions treated between January 2021 and June 2025. All had severe claudication (Rutherford class 3) and calcified lesions. All underwent ipsilateral retrograde popliteal access, JetStream rotational atherectomy, and Ranger DCB post-dilatation (Boston Scientific) without embolic protection. Technical success, access-site safety, ankle-brachial index (ABI), and 12-month patency were evaluated.
resultsMean age was 69.9 ± 7.9 years; 18 (81.8%) were male. Technical success was 95.5% (one bailout stent). No embolic events, procedure-related deaths, amputations, or major complications occurred. One patient (4.5%) had a minor access-site hematoma. At 12 months (19 patients), Kaplan-Meier analysis demonstrated a primary patency rate of 89.9% and a secondary patency rate of 100% (as all TLRs were successful). Two patients required clinically driven target lesion revascularization (TLR) at 6 and 10 months; freedom from TLR at 12 months was 89.9%. Mean ABI improved from 0.47 ± 0.07 to 0.85 ± 0.11 at 1 month (P < .001) and remained stable at 12 months (0.86 ± 0.04).
conclusionsRPA combined with rotational atherectomy and DCB angioplasty without embolic protection was technically feasible and did not result in clinically detectable macroembolization. However, definitive conclusions regarding microembolic safety cannot be drawn from these data alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.